Healthcare provider profile · identity verified

Anna Raye Niesen, PA-C

Physician Assistant · PRINCETON, MN · NPI 1891165692

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	240	81
Levothyroxine Sodium	Levothyroxine Sodium	239	67
Lisinopril	Lisinopril	222	69
Simvastatin	Simvastatin	209	66
Losartan Potassium	Losartan Potassium	195	64
Omeprazole	Omeprazole	173	57
Amlodipine Besylate	Amlodipine Besylate	150	48
Gabapentin	Gabapentin	147	49
Metoprolol Succinate	Metoprolol Succinate	139	44
Sertraline Hcl	Sertraline Hcl	98	27
Tramadol Hcl	Tramadol Hcl	96	14
Metformin Hcl Er	Metformin Hcl	84	28
Hydrochlorothiazide	Hydrochlorothiazide	81	28
Albuterol Sulfate Hfa	Albuterol Sulfate	73	24
Oxycodone Hcl	Oxycodone Hcl	72	17
Citalopram Hbr	Citalopram Hydrobromide	71	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	67	26
Metformin Hcl	Metformin Hcl	67	21
Fluticasone Propionate	Fluticasone Propionate	64	27
Rosuvastatin Calcium	Rosuvastatin Calcium	60	18
Bupropion Xl	Bupropion Hcl	58	19
Glipizide Er	Glipizide	58	16
Trazodone Hcl	Trazodone Hcl	56	19
Metoprolol Tartrate	Metoprolol Tartrate	55	14
Hydroxyzine Hcl	Hydroxyzine Hcl	54	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	53	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	50	15
Atenolol	Atenolol	49	18
Furosemide	Furosemide	46	15
Meloxicam	Meloxicam	46	19
Escitalopram Oxalate	Escitalopram Oxalate	45	12
Alendronate Sodium	Alendronate Sodium	42	17
Famotidine	Famotidine	42	16
Amitriptyline Hcl	Amitriptyline Hcl	41	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	40	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	40	15
Ozempic	Semaglutide	38	suppressed
Tizanidine Hcl	Tizanidine Hcl	37	12
Prednisone	Prednisone	34	27
Diazepam	Diazepam	33	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	11
Triamcinolone Acetonide	Triamcinolone Acetonide	32	17
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Jardiance	Empagliflozin	30	suppressed
Pregabalin	Pregabalin	30	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Mounjaro	Tirzepatide	29	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	29	suppressed
Ventolin Hfa	Albuterol Sulfate	29	15
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Spironolactone	Spironolactone	28	11
Tamsulosin Hcl	Tamsulosin Hcl	28	suppressed
Alprazolam	Alprazolam	27	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	27	suppressed
Oxycontin	Oxycodone Hcl	27	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Eliquis	Apixaban	25	12
Montelukast Sodium	Montelukast Sodium	25	suppressed
Sucralfate	Sucralfate	25	suppressed
Testosterone Cypionate	Testosterone Cypionate	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Clonazepam	Clonazepam	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Baclofen	Baclofen	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Jantoven	Warfarin Sodium	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	15
Fluconazole	Fluconazole	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Allopurinol	Allopurinol	15	suppressed
Azithromycin	Azithromycin	15	12
Ibuprofen	Ibuprofen	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Metronidazole	Metronidazole	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Carisoprodol	Carisoprodol	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Topiramate	Topiramate	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Ascomp With Codeine	Codeine/Butalbital/Asa/Caffein	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Temazepam	Temazepam	12	suppressed
Budesonide Dr	Budesonide	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Finasteride	Finasteride	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error